Aims: K ATP ion channels play a key role in glucose-stimulated insulin secretion.
| INTRODUC TI ON
The role of the pancreatic beta-cell K ATP ion channel in the regulation of insulin secretion is well characterized. 1 An extensive range of compounds is known to block the K ATP channel; canonically these are sulphonylureas, such as tolbutamide, 2 gliclazide, 3 glipizide 4 and glibenclamide 2, 4 ; and glitinides, such as meglitinide 2 and repaglinide. 5 The ability of these drugs to selectively block K ATP in pancreatic beta cells underlies their use in the treatment of hyperglycaemia. 4 However, many other structurally diverse drugs can also block K ATP as an "off target"; where inadvertent block of the pancreatic beta-cell K ATP channel can lead to the adverse effects of hyperinsulinaemia and hypoglycaemia seen in the clinic, for example following over dosage with quinolones in the treatment of malaria. 6 Indeed, most studies that have investigated the ability of nonsulphonylurea drugs to block beta-cell K ATP channel activity and stimulate insulin secretion have arisen from clinical reports of adverse hypoglycaemic episodes during their acute usage; as reported for thiazolidinediones, 7, 8 quinolones, 6 ,9 fluoroquinolones 10 and pheniramines. 11 Although no obvious common structural chemical moieties underlie the "off target" action of these drugs, they do all share the common property of lipophilicity. As a trend between the potency to block K ATP and lipophilicity is noted for barbiturates 12 whether this also extends to other, nonsulphonylurea, blockers of K ATP is unknown.
Statins, that is 3-hydroxy-3-methyl glutaryl coenzyme A (HMGCoA) reductase inhibitors, are compounds currently used to treat hypercholesterolaemia. These drugs widely differ in their water solubility, and clinical trials have highlighted an association between their lipophilicity and risk of glucose intolerance and diabetes with chronic use 13 ; however, these drugs, unlike other lipophilic drugs,
are not reported to produce hypoglycaemia with acute use. The question arises as to whether statins can block K ATP and if lipophilicity is indeed a useful predictor for the potency of a compound to block this ion channel? If so, we can then ask the questions as to whether statins promote Ca 2+ influx, and if so, query their inability to stimulate insulin release in vivo?
The primary aim of this study was to determine the relationship between drug lipophilicity and block of K ATP by a meta-analysis and then to test whether this relationship could reliably predict the potency of other drugs to affect the activity of pancreatic β-cell K ATP channels and insulin secretion.
| MATERIAL S AND ME THODS

| Relationship between Log IC 50 and the logP for the block of K ATP
The Log IC 50 of 26 compounds that block beta-cell K ATP channel activity was extracted from publications given in Figure 1 . ca and were confirmed from the original source references to be within the physiological pH range 7-8 to account for neutral and ionized species in the aqueous phase. When an experimental logP was unavailable, as was the case for cibenzoline, ciclazindol, englitazone, 2-n-hexyl-4-benzoxazine, temafloxacin, terfenadine and Triton X-100, it was calculated from quantitative structural activity relationship calculations (QSAR) at www.Chemicalize.com. To determine whether a relationship existed between Log IC 50 and logP
Pearson correlation was performed, and the data were described by linear regression with PRISM version 7 (GraphPad, San Diego, CA, USA).
| Preparation of β cells
Primary pancreatic β cells were dissociated from islets of male CD1 mice (30-50 g; 3-6 months old). 14 All animal care and experimental procedures were carried out in accordance with either the UK Insulin is expressed in relation to total protein content (Pierce BCA protein kit; Thermo Scientific, USA). 
| Intracellular Ca
| Statistical analysis
Statistical analysis was performed using PRISM, and data were 
Data are given as the mean ± SEM or median with 5%-95% confidence intervals (C.I.), with n the number of experimental units.
Statistical significance is defined as P < .05 and is flagged as * in graphics. ). These data demonstrate that the effect of simvastatin is independent of glucose metabolism, intracellular Mg 2+ and cytosolic factors. 20 μmol/L tolbutamide and 100 nmol/L simvastatin inhibited K ATP channel activity in standard whole cell by 43 ± 3.3% (n = 9) and 47 ± 3.1%, respectively (n = 5; Figure 3C -E). The IC 50 for simvastatin estimated from the whole-cell data: 31 nmol/L (20-42 nmol/L, 95% C.I.) was almost identical to that measured for the IO patches (26 nmol/L; Figure 3F ). Both the onset and washout of tolbutamide block were complete within 1 minute, unlike that for simvastatin, which took at least 10 minutes to achieve steady-state block and was irreversible.
| RE SULTS
| Simvastatin stimulates Ca
2+ influx
In the presence ( Figure 4A ), but not the absence ( Figure 4D ), of 2 mmol/L glucose, 100 nmol/L simvastatin elicited an increase in
[Ca
2+
] i similar to that with 20 μmol/L tolbutamide ( Figure 4A ). An
observation of an increase in [Ca
2+
] i by 100 nmol/L simvastatin over a 15-minute incubation had an odds ratio of 10.8 (3-39, 95% C.I., P = .0001) relative to its DMSO vehicle control.
| Simvastatin failed to affect insulin secretion
Neither pravastatin nor simvastatin affected basal or glucosestimulated insulin secretion from mouse pancreatic islets at the 2 concentrations tested (100 nmol/L and 1 μmol/L; Figure 5A ,B). As the failure of simvastatin to effect insulin secretion may be due to serum sequestration, the effect of BSA on the efficacy of the drug to block K ATP was explored. In whole-cell records, 0.5% BSA significantly decreased the efficacy of 1 μmol/L simvastatin by 10-fold to an amount similar to that found with 100 nmol/L of the drug ( Figure 5C ). In cell-attached patches, 0.1% BSA abolished the ability of 100 nmol/L simvastatin to inhibit K ATP activity (NPo) and depolarize Vm ( Figure 5D ).
| D ISCUSS I ON
The Log IC 50 for the block of K ATP by lipophilic drugs, except for the second-generation sulphonylureas, was positively correlated with their logP. Moreover, this relationship accurately predicted the Log IC 50 for the block of K ATP by simvastatin and pravastatin.
The observation that Log IC 50 of K ATP block by a drug is related to its logP has already been described for barbiturates. 12 However, The pancreatic β-cell K ATP channel is an octamer composed of 4
Kir6.2 and 4 SUR1 subunits, the latter associated with the specific binding of sulphonylureas. and 2-n-4-benzoxazines, 30 but not high-affinity sulphonylureas. 22, 23 A decrease in intracellular Mg 2+ is established to reduce the potency of glitinides and sulphonylureas to inhibit K ATP activity but not that of other drugs 2, 4, 22 ; an effect thought to be due to disruption of the interaction between the SUR1 and Kir6.2 subunits. Consequently, 2-n-hexyl-4-benzoxazines 30 ; and terfenadine. 2 As the block of K ATP channel activity by simvastatin was also unaffected by intracellu-
lar [Mg
2+
] i , it supports the idea that its block of K ATP is by a direct interaction with the Kir6.2 pore subunit. The fact that neither lipophobic pravastatin (logP 0.59) nor DMSO (logP −1.35) inhibited K ATP channel activity lends support to an intramembrane effect for simvastatin and the other lipophilic drugs.
The slowness and apparent irreversibility for the block of K ATP by simvastatin are consistent with an intramembrane effect, especially as other slow blockers of K ATP of similar lipophilicity, for example englitazone 8 and Triton X-100, 24 are similarly slow in onset and irreversible. idea that lipophilic compounds affect ion channel gating by altering the bilayer elastic properties and the ability of an ion channel to reorganize its protein structure during gating transitions, 33 moreover, the same argument also abrogates an interaction of statins with K ATP channels as an explanation for the adverse metabolic actions seen with chronic use of these drugs. We also expect little effect on the Kir6.2 pore subunit expressed in skeletal and cardiac muscle, as these channels are majorly closed under physiological conditions. 36 To conclude, we demonstrate that logP, a measure of lipophilicity, can predict the potency of a drug to block K ATP channels without the need to consider complex quantitative structural activity relationships and suggest that the logP can be used as a simple aid to predict the potential of a drug, new or old, to inhibit beta-cell K ATP . However, whether such drugs cause hyperinsulinaemia appears dependent on their absolute IC 50 and free plasma concentration.
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